The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 64 , ISSUE 2 ( April-June, 2022 ) > List of Articles

Original Article

Clinico-pathological Profile of Lung Cancer Patients in a Tertiary Care Hospital, India: A Prospective, Cross-sectional Study

Ramniwas, Rajani Kumawat, Ayush Gupta, Dipak Bhattacharya, Jagdish C Suri

Keywords : Clinico-pathological profile, India, Lung cancer, Molecular profile

Citation Information : Ramniwas, Kumawat R, Gupta A, Bhattacharya D, Suri JC. Clinico-pathological Profile of Lung Cancer Patients in a Tertiary Care Hospital, India: A Prospective, Cross-sectional Study. Indian J Chest Dis Allied Sci 2022; 64 (2):79-85.

DOI: 10.5005/jp-journals-11007-0002

License: CC BY-NC 4.0

Published Online: 08-07-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Background: Adenocarcinoma (ADC) is the commonest subtype of lung cancer, though a number of studies in India have observed squamous cell carcinoma (SCC) to be the commonest histology. Majority of Indian studies on clinico-pathological profile are retrospective and there is limited data on comparison of demographic, clinical, and radiological features among histological subgroups of lung cancer. Methods: Three-hundred and twelve consecutive confirmed cases of lung cancer diagnosed from December 2014 to January 2017 were enrolled prospectively. Data pertaining to the demographic, clinical, radiological, pathological, and molecular profile were analyzed. Results: Their mean age was 57.2 ± 10.8 years. Of all the lung cancer patients studied, 80.5% were males and 73.4% were smokers. Across all histological subtypes, the commonest symptom was cough (76.9%). Chest pain, hoarseness of voice, dysphagia, and neck veins engorgement were significantly higher in small cell lung carcinoma (SCLC) cases, while hemoptysis in SCC cases. The most common radiological finding was a mass lesion predominantly located, peripherally in cases with ADC and SCC lung, while centrally in SCLC. The most common site for distant metastasis was the bone (32.5%), followed by the liver, adrenal, brain, and other organs. ADC, SCC, and SCLC constituted 48.1, 32.1, and 14.4%, respectively. Incidence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in ADC patients were 26.5% and 7.8%, respectively, with a predilection for nonsmokers. The most common EGFR mutation was exon 19 deletions. Conclusions: Adenocarcinoma lung may now be replacing SCC as the commonest type of lung cancer in Northern India. The overall incidence of EGFR mutations in ADC patients was 26.5%, with exon 19 deletion being the most common mutation.

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69(1):7–34. DOI: 10.3322/caac.21551.
  2. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review 1975-2017. Bethesda: National Cancer Institute. Available at:
  3. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492.
  4. Noronha V, Dikshit R, Raut N, et al. Epidemiology of lung cancer in India: focus on the differences between non-smokers and smokers: a single-centre experience. Indian J Cancer 2012;49(1):74–81. DOI: 10.4103/0019-509X.98925.
  5. Behera D. Lung cancer in India. Med Update 2012;22:401–407.
  6. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947–957. DOI: 10.1056/NEJMoa0810699.
  7. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101(36):13306–13311. DOI: 10.1073/pnas.0405220101.
  8. Dey A, Biswas D, Sahu SK, et al. Comparison study of clinicoradiological profile of primary lung cancer cases: an Eastern India experience. Indian J Cancer 2012;49(1):89–95. DOI: 10.4103/0019-509X.98930.
  9. Prasad R, Ahuja RC, Singhal S, et al. A case-control study of bidi smoking and bronchogenic carcinoma. Ann Thorac Med 2010;5(4):238–241. DOI: 10.4103/1817-1737.69116.
  10. Prasad R, James P, Kesarwani V, et al. Clinicopathological study of bronchogenic carcinoma. Respirology 2004;9(4):557–560. DOI: 10.1111/j.1440-1843.2004.00600.x.
  11. Malik PS, Sharma MC, Mohanti BK, et al. Clinico-pathological profile of lung cancer at AIIMS: a changing paradigm in India. Asian Pac J Cancer Prev 2013;14(1):489–94. DOI: 10.7314/apjcp.2013.14.1.489.
  12. Kaur H, Sehgal IS, Bal A, et al. Evolving epidemiology of lung cancer in India: reducing non-small cell lung cancer-not otherwise specified and quantifying tobacco smoke exposure are the key. Indian J Cancer 2017;54(1):285–290. DOI: 10.4103/ijc.IJC_597_16.
  13. Jindal SK, Behera D. Clinical spectrum of primary lung cancer review of Chandigarh experience of 10 years. Lung India 1990;8(2):94–98.
  14. Mohan A, Garg A, Gupta A, et al. Clinical profile of lung cancer in North India: a 10-year analysis of 1862 patients from a tertiary care center. Lung India 2020;37(3):190–197. DOI: 10.4103/lungindia.lungindia_333_19.
  15. Sundaram V, Sanyal N. Clinicopathological profile of bronchogenic carcinoma in a tertiary care hospital in eastern part of India. Clin Cancer Investig J 2014;3(3):220–224. DOI: 10.4103/2278-0513.132114.
  16. Mishra S, Joseph RA, Gupta PC, et al. Trends in bidi and cigarette smoking in India from 1998 to 2015, by age, gender and education. BMJ Global Health 2016;1(1):e000005. DOI: 10.1136/bmjgh-2015-000005.
  17. Rawat J, Sindhwani G, Gaur D, et al. Clinico-pathological profile of lung cancer in Uttarakhand. Lung India 2009;26(3):74–76. DOI: 10.4103/0970-2113.53229.
  18. Gupta RC, Purohit SD, Sharma MP, et al. Primary bronchogenic carcinoma: clinical profile of 279 cases from mid-west Rajasthan. Indian J Chest Dis Allied Sci 1998;40:109–116. PMID: 9775568.
  19. Dattatreya SP, Bansal R, Vamsy M, et al. Clinicopathological profile of lung cancer at a tertiary care center. Indian J Cancer 2018;55(3):273–275. DOI: DOI: 10.4103/ijc.IJC_455_17.
  20. Fernando LW, Luis CL, Edson OA, et al. Characteristics of patients with lung cancer in the city of manus, Brazil. J Bras Pneumol 2009;35(2):157. DOI: 10.1590/s1806-37132009000200009.
  21. Blanchon F, Grivaux M, Asselain B, et al. 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol 2006;7(10):829–836. DOI: 10.1016/S1470-2045(06)70868-3.
  22. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24(28):4539–4544. DOI: 10.1200/JCO.2005.04.4859.
  23. Grivaux M, Zureik M, Marsal L, et al. Five-year survival for lung cancer patients managed in general hospitals. Rev Mal Respir 2011;28(7): 31–38. DOI: 10.1016/j.rmr.2008.07.001.
  24. Dhandapani S, Srinivasan A, Rajagopalan R, et al. Clinicopathological profile of lung cancer patients in a teaching hospital in South. Indian J Cardio Thorac Med 2016;4(2):440–443.
  25. Valaitis J, Warren S, Gamble D. Increasing incidence of adenocarcinoma of the lung. Cancer 1981;47(5):1042–1046. DOI: 10.1002/1097-0142(19810301)47:5<1042::aid-cncr2820470535>;2-5.
  26. Doval DC, Azam S, Batra U, et al. Epidermal growth factor receptor mutation in lung adenocarcinoma in India: a single center study. J Carcinog 2013;12:12. DOI: 10.4103/1477-3163.114970.
  27. Veldore VH, Rao RM, Kakara S, et al. Epidermal growth factor receptor mutation in nonsmallcell lung carcinomas: a retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India. Indian J Cancer 2013;50(2):87–93. DOI: 10.4103/0019-509X.117013.
  28. Pungliya M, Sachin M, Soumittra N, et al. A study of incidence of EGFR mutations in non-smoker adenocarcinoma of the lung: disparity between North and South Indian patients. J Cancer Ther Res 2014;3:4. DOI: 10.7243/2049-7962-3-4(3):4.
  29. Maturu VN, Singh N, Bal A, et al. Relationship of epidermal growth factor receptor activating mutations with histologic subtyping according to International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society 2011 adenocarcinoma classification and their impact on overall survival. Lung India 2016;33(3):257–266. DOI: 10.4103/0970-2113.180801.
  30. Wong DW, Leung EL, So KK, et al. University of Hong Kong Lung Cancer Study Group. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115(8):1723–1733. DOI: 10.1002/cncr.24181.
  31. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010;9:188. DOI: 10.1186/1476-4598-9-188.
  32. Desai SS, Shah AS, Prabhash K, et al. A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives. Indian J Cancer 2013;50(2):80–86. DOI: 10.4103/0019-509X.117007.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.